Small molecule · developed by Maze Therapeutics
MZE829 is an oral capsule formulation.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06830629 | Phase 2 | Proteinuric Kidney Disease | Recruiting | MAZE |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Proteinuric Kidney Disease
Updated Oct 18, 2026. Something wrong or missing? Report it on the MAZE page.
See MAZE's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
MAZE catalysts and pipeline →